The latest announcement is out from Jaguar Animal Health ( (JAGX) ).
On March 13, 2025, Jaguar Health held a special meeting where stockholders approved two proposals, including a reverse stock split of the company’s common stock. The company is advancing its plant-based drug, crofelemer, for rare diseases and cancer therapy-related diarrhea, with expected trial results and regulatory discussions in 2025. These developments could enhance Jaguar’s market positioning and offer new treatment pathways, potentially benefiting stakeholders.
More about Jaguar Animal Health
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing novel proprietary prescription medicines derived from plants in rainforest areas. The company targets gastrointestinal distress, including symptoms like chronic diarrhea and bowel incontinence. Its subsidiary, Napo Pharmaceuticals, develops human prescription pharmaceuticals for managing neglected gastrointestinal symptoms, while Napo Therapeutics focuses on expanding access to crofelemer in Europe for orphan and rare diseases.
YTD Price Performance: -55.96%
Average Trading Volume: 431,014
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.82M
For an in-depth examination of JAGX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com